Here is the design of a clinical trial:

Official Title: Protocol of the PE37 Study: a Multicenter Randomized Trial of Screening with SFlt1/PlGF and Planned Delivery to Prevent Preeclampsia At Term

Included conditions:
- Preeclampsia
- Intrauterine Growth Restriction
- Maternal Hypertension
- Neonatal Outcome
- Perinatal Death

Study Armgroups:
- {'label': 'Non-intervention or non-reveal group', 'type': 'NO_INTERVENTION', 'description': 'Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery'}
- {'label': 'Intervention group or reveal group', 'type': 'EXPERIMENTAL', 'description': 'A ratio cutoff of \\>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation', 'interventionNames': ['Diagnostic Test: sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation']}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation', 'description': 'A ratio cutoff of \\>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation', 'armGroupLabels': ['Intervention group or reveal group']}

Primary Outcomes:
- {'measure': 'Rate of term Preeclampsia development', 'description': 'Number of participants with term preeclampsia/total number participants.', 'timeFrame': '4 weeks'}

Please estimate the sample size based on the assumption: 
90% statistical power, 10% loss, 99% power for non-inferiority hypothesis testing
Sample size
        A sample size of 8302 is needed to guarantee a 90% statistical power for demonstrating a 50% reduction (assuming a detection rate of 70% and a 70% risk-reduction by timely induction) in the development of PE (from 1.5%).27 Assuming a 10% loss, the investigators estimated a sample size of 9132âwomen.
        Under a non-inferiority hypothesis testing design, assuming a composite adverse neonatal outcome incidence of 1% in the revealed group, 0.5% in the concealed risk and a prespecified non-inferiority margin of 0.25%; this sample size (4151 per arm) would result in a power of 99% to reject the null hypothesis that the reveal strategy increases the neonatal complications.27